PURPOSE: Unstable plaques may cause clinical events. Plaque destabilization results from the synergy between intraplaque angiogenesis and inflammation. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are considered to be involved in these processes. We investigated the efficacy of the anti-VEGFR mimic single-chain VEGF (scVEGF) to map intra-plaque VEGFR expression and atherosclerotic plaque instability using near-infrared fluorescence (NIRF). PROCEDURES: Human carotid plaques were retrieved from 15 symptomatic and five asymptomatic patients. NIRF plaque imaging was performed pre-/post-incubation with scVEGF/Cy5.5. Biopsies taken from regions with high (hot spot) and low (cold spot) NIRF signals were examined for VEGF-A, VEGFR-1 and VEGFR-2 mRNA expression levels using real-time RT-PCR analysis. Immunohistochemistry for CD31 (endothelium), CD68 (macrophages) and αSMA (smooth muscle cells) was performed to evaluate plaque composition. RESULTS: NIRF imaging of 20 plaques revealed a heterogeneous distribution of scVEGF/Cy5.5 binding. After incubation NIRF activity increased from 3.9×10(-5) ± 5.2×10(-6) to 3.0×10(-4) ± 2.2×10(-5) and 5.8×10(-5) ± 1.9×10(-5) to 3.1×10(-4) ± 1.9×10(-5) photons/s/cm(2)/sr/illumination intensity on the intraluminal and extraluminal side, respectively (both p < 0.001). Real-time RT-PCR analysis showed a ~1.2- and ~16.4-fold increased mRNA expression of VEGFR-1 and VEGFR-2, respectively, in hot spots (vs. cold spots). Immunohistochemistry exhibited higher intraplaque capillary density in hot spots (vs. cold spots) (17.2 ± 3.7 vs. 5.4 ± 2.2 capillary/mm(2); p = 0.037). Hot spots contained significantly reduced numbers of α-SMA-positive cells (vs. cold spots) (2.2 ± 0.7 % vs. 6.9 ± 1.5 %; p = 0.038). Finally, a ~2-fold increase of CD68(+) infiltrating macrophages within hot spots (vs. cold spots) was observed (not significant, p = 0.17). Significant higher capillary density in hot spots (vs. cold spots) was observed in plaques from symptomatic patients but not in plaques from asymptomatic patients. CONCLUSION: Our data support that scVEGF/Cy5.5 is a suitable indicator for plaque instability and a promising diagnostic tool for risk assessment in cardiovascular diseases.
PURPOSE: Unstable plaques may cause clinical events. Plaque destabilization results from the synergy between intraplaque angiogenesis and inflammation. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are considered to be involved in these processes. We investigated the efficacy of the anti-VEGFR mimic single-chain VEGF (scVEGF) to map intra-plaque VEGFR expression and atherosclerotic plaque instability using near-infrared fluorescence (NIRF). PROCEDURES: Human carotid plaques were retrieved from 15 symptomatic and five asymptomatic patients. NIRF plaque imaging was performed pre-/post-incubation with scVEGF/Cy5.5. Biopsies taken from regions with high (hot spot) and low (cold spot) NIRF signals were examined for VEGF-A, VEGFR-1 and VEGFR-2 mRNA expression levels using real-time RT-PCR analysis. Immunohistochemistry for CD31 (endothelium), CD68 (macrophages) and αSMA (smooth muscle cells) was performed to evaluate plaque composition. RESULTS: NIRF imaging of 20 plaques revealed a heterogeneous distribution of scVEGF/Cy5.5 binding. After incubation NIRF activity increased from 3.9×10(-5) ± 5.2×10(-6) to 3.0×10(-4) ± 2.2×10(-5) and 5.8×10(-5) ± 1.9×10(-5) to 3.1×10(-4) ± 1.9×10(-5) photons/s/cm(2)/sr/illumination intensity on the intraluminal and extraluminal side, respectively (both p < 0.001). Real-time RT-PCR analysis showed a ~1.2- and ~16.4-fold increased mRNA expression of VEGFR-1 and VEGFR-2, respectively, in hot spots (vs. cold spots). Immunohistochemistry exhibited higher intraplaque capillary density in hot spots (vs. cold spots) (17.2 ± 3.7 vs. 5.4 ± 2.2 capillary/mm(2); p = 0.037). Hot spots contained significantly reduced numbers of α-SMA-positive cells (vs. cold spots) (2.2 ± 0.7 % vs. 6.9 ± 1.5 %; p = 0.038). Finally, a ~2-fold increase of CD68(+) infiltrating macrophages within hot spots (vs. cold spots) was observed (not significant, p = 0.17). Significant higher capillary density in hot spots (vs. cold spots) was observed in plaques from symptomatic patients but not in plaques from asymptomatic patients. CONCLUSION: Our data support that scVEGF/Cy5.5 is a suitable indicator for plaque instability and a promising diagnostic tool for risk assessment in cardiovascular diseases.
Authors: P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico Journal: Nat Med Date: 2001-05 Impact factor: 53.440
Authors: D Feng; J A Nagy; R A Brekken; A Pettersson; E J Manseau; K Pyne; R Mulligan; P E Thorpe; H F Dvorak; A M Dvorak Journal: J Histochem Cytochem Date: 2000-04 Impact factor: 2.479
Authors: K D O'Brien; M D Allen; T O McDonald; A Chait; J M Harlan; D Fishbein; J McCarty; M Ferguson; K Hudkins; C D Benjamin Journal: J Clin Invest Date: 1993-08 Impact factor: 14.808
Authors: Rute Moura; Marc Tjwa; Petra Vandervoort; Soetkin Van Kerckhoven; Paul Holvoet; Marc F Hoylaerts Journal: Circ Res Date: 2008-09-25 Impact factor: 17.367
Authors: Alessandro Mauriello; Giuseppe M Sangiorgi; Renu Virmani; Santi Trimarchi; David R Holmes; Frank D Kolodgie; David G Piepgras; Giulia Piperno; Doriana Liotti; Jagat Narula; Paolo Righini; Arnaldo Ippoliti; Luigi G Spagnoli Journal: Atherosclerosis Date: 2009-08-03 Impact factor: 5.162
Authors: Wael E Shaalan; Hongwei Cheng; Bruce Gewertz; James F McKinsey; Lewis B Schwartz; Daniel Katz; Dindcai Cao; Tina Desai; Seymour Glagov; Hisham S Bassiouny Journal: J Vasc Surg Date: 2004-08 Impact factor: 4.268
Authors: Reza Golestani; Leila Mirfeizi; Clark J Zeebregts; Johanna Westra; Hans J de Haas; Andor W J M Glaudemans; Michel Koole; Gert Luurtsema; René A Tio; Rudi A J O Dierckx; Hendrikus H Boersma; Philip H Elsinga; Riemer H J A Slart Journal: J Nucl Cardiol Date: 2015-02-20 Impact factor: 5.952
Authors: Yared Tekabe; Maria Kollaros; Adam Zerihoun; Geping Zhang; Marina V Backer; Joseph M Backer; Lynne L Johnson Journal: EJNMMI Res Date: 2014-08-01 Impact factor: 3.138
Authors: H M Schouw; L A Huisman; H H Boersma; S Kruijff; Y F Janssen; R H J A Slart; R J H Borra; A T M Willemsen; A H Brouwers; J M van Dijl; R A Dierckx; G M van Dam; W Szymanski Journal: Eur J Nucl Med Mol Imaging Date: 2021-10-11 Impact factor: 9.236
Authors: Isabella Albanese; Stella S Daskalopoulou; Bin Yu; Zhipeng You; Jacques Genest; Alawi Alsheikh-Ali; Adel G Schwertani Journal: Front Pharmacol Date: 2016-06-07 Impact factor: 5.810